CSF3 and COVID-19: Together, these results provide in silico evidence that people with genetically higher plasma G-CSF abundances are less likely to develop (severe) COVID-19 and suggest that treatment with rhG-CSF might decrease the risk for symptomatic or even severe COVID-19.